Cortical blindness and seizures in a patient receiving FK506 after bone marrow transplantation

Authors
Steg, RE Kessinger, A Wszolek, ZK
Citation
Re. Steg et al., Cortical blindness and seizures in a patient receiving FK506 after bone marrow transplantation, BONE MAR TR, 23(9), 1999, pp. 959-962
Citations number
10
Categorie Soggetti
Hematology,"Medical Research Diagnosis & Treatment
Journal title
BONE MARROW TRANSPLANTATION
ISSN journal
02683369 → ACNP
Volume
23
Issue
9
Year of publication
1999
Pages
959 - 962
Database
ISI
SICI code
0268-3369(199905)23:9<959:CBASIA>2.0.ZU;2-6
Abstract
A 54-year-old woman with a myelodysplastic syndrome treated with high-dose chemotherapy and an allogenic bone marrow transplant developed acute cortic al blindness while receiving tacrolimus (FK506). MRI showed white matter ab normalities. After discontinuation of FK506, the patient's vision returned within 8 days. FK506 neurotoxicity is similar to cyclosporine neurotoxicity and can occur in allogenic bone marrow transplant patients treated with FK 506.